Eczema - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 45 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Eczema - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Eczema - Pipeline Review, H2 2014', provides an overview of the Eczema's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Eczema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Eczema and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Eczema
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Eczema and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Eczema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Eczema pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Eczema
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Eczema pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Eczema Overview 6
Therapeutics Development 7
Pipeline Products for Eczema - Overview 7
Pipeline Products for Eczema - Comparative Analysis 8
Eczema - Therapeutics under Development by Companies 9
Eczema - Therapeutics under Investigation by Universities/Institutes 10
Eczema - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Eczema - Products under Development by Companies 14
Eczema - Products under Investigation by Universities/Institutes 15
Eczema - Companies Involved in Therapeutics Development 16
Merck & Co., Inc. 16
FAES Farma SA 17
China Biologic Products, Inc. 18
GlycaNova Norway AS 19
Immune Response BioPharma, Inc. 20
Eczema - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
bilastine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
desloratadine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Drug for Atopic Dermatitis and Eczema - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Varicella Hyperimmune Globulins - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
IR-444 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
MM-1501 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Eczema - Recent Pipeline Updates 34
Eczema - Dormant Projects 35
Eczema - Discontinued Products 36
Eczema - Product Development Milestones 37
Featured News & Press Releases 37
Oct 21, 2013: Celsus Therapeutics' MRX-6 Selected as One of the "Top Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Elsevier Business Intelligence 37
Nov 05, 2012: Creabilis Receives £1.42m Biomedical Catalyst Grant For Development Of CT327 38
Jul 11, 2012: US Government Expands Population Eligible To Receive Bavarian Nordic's Smallpox Vaccine In Emergency 38
Jun 25, 2012: Flower power may be answer to itchy problem 39
May 04, 2012: Anacor To Present Clinical Data On AN2728 At Upcoming Medical Meetings 40
Apr 20, 2012: HanAll BioPharma Initiates Phase II Trial Of Anti-Atopic Dermatitis Gel In US 40
Feb 07, 2012: Anacor Announces Positive Preliminary Results From Two Safety Studies Of AN2728 41
Dec 12, 2011: Anacor Announces Positive Preliminary Results From Phase IIa Trial Of AN2728 In Atopic Dermatitis 41
Dec 12, 2011: Anacor Pharmaceuticals Announces Positive Preliminary Results From Phase IIa Trial Of AN2898 In Atopic Dermatitis 42
May 27, 2011: Creabilis Presents CT327 To 22nd World Congress Of Dermatology In Seoul, Korea 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables
Number of Products under Development for Eczema, H2 2014 7
Number of Products under Development for Eczema - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Eczema - Pipeline by Merck & Co., Inc., H2 2014 16
Eczema - Pipeline by FAES Farma SA, H2 2014 17
Eczema - Pipeline by China Biologic Products, Inc., H2 2014 18
Eczema - Pipeline by GlycaNova Norway AS, H2 2014 19
Eczema - Pipeline by Immune Response BioPharma, Inc., H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Eczema Therapeutics - Recent Pipeline Updates, H2 2014 34
Eczema - Dormant Projects, H2 2014 35
Eczema - Discontinued Products, H2 2014 36